CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 288 enrolled
Drug / intervention
CR845drug
Likely dose
CR845 0.5 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03281538
NCT03281538Phase 3Completed
CompareCT.gov

An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Cara Therapeutics, Inc.·interventional·Posted Sep 13, 2017·Updated Oct 14, 2021

In Brief

A Phase 3 clinical trial evaluating CR845 for Uremic Pruritus. Completed, enrolled 288 participants across 27 sites in 2 countries.

Detailed Summary

This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUremic Pruritus
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 13, 2017
Enrollment StartAug 14, 2017
Primary CompletionFeb 11, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.8 years ago

Interventions

CR845drug

IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)